Compare CDIO & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDIO | CPHI |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | China |
| Employees | 9 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 6.1M |
| IPO Year | N/A | 2008 |
| Metric | CDIO | CPHI |
|---|---|---|
| Price | $2.60 | $0.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 6.6M | 10.6K |
| Earning Date | 03-13-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 70.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,528,929.00 |
| Revenue This Year | $171,906.75 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.18 | $0.12 |
| 52 Week High | $7.91 | $14.00 |
| Indicator | CDIO | CPHI |
|---|---|---|
| Relative Strength Index (RSI) | 41.73 | 32.53 |
| Support Level | $1.26 | $0.50 |
| Resistance Level | $4.24 | $0.65 |
| Average True Range (ATR) | 0.82 | 0.05 |
| MACD | -0.39 | 0.02 |
| Stochastic Oscillator | 9.18 | 33.20 |
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.